Rothschild & Co Redburn initiated coverage of Balchem (BCPC) with a Neutral rating and $162 price target The company has a “resilient” business model built upon niche high-growth products, the analyst tells investors in a research note. However, the firm finds Balchem’s valuation as “rich” at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCPC:
- Balchem management to meet with Clear Street
- Balchem’s Cognitive Supplement Study: A Potential Game-Changer for Cognitive Health?
- Balchem’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Balchem price target raised to $190 from $189 at H.C. Wainwright
- Balchem Corporation Reports Record Third-Quarter Growth